Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa

Lau, Daryl T.Y.; Everhart, James E.; Kleiner, David E.; Park, Y.; Vergalla, John; Schmid, Peter; Hoofnagle, Jay H.

doi:10.1053/gast.1997.v113.pm9352870

Cited by 301 publications

(188 citation statements)

References 1 publication

Supporting

Mentioning

176

Contrasting

Unclassified

Order By: Relevance

“…The lamivudine response rates seen here, which approximate those achieved with interferon, indicate a high probability of persistent benefit. 2,10,11 When we designed the protocol for this trial, patients who were derived from previous studies had durable HBeAg seroconversions for at least 12 to 16 weeks after cessation of initial lamivudine therapy. In those "feeder" studies, durability of HBeAg seroconversion during the 3 to 4 post-treatment months was approximately 80%.…”

Section: Discussionmentioning

confidence: 99%

Durability of Serologic Response After Lamivudine Treatment of Chronic Hepatitis B

et al. 2003

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Durability of Serologic Response After Lamivudine Treatment of Chronic Hepatitis B

et al. 2003

View full text Add to dashboard Cite

“…[3][4][5] Disappearance of HBeAg, whether spontaneous or post-antiviral treatment, reduces the risk of hepatic impairment and increases survival. [8][9][10][11] Nevertheless, 10%-30% of the patients can still present high ALT and high levels of HBV-DNA after HBeAg seroconversion and 10%-20% of the inactive carriers may reactivate HBV replication and have exacerbation of hepatitis after years of quiescence. [12][13][14] Most hepatitis flares, after HBeAg seroconversion occur within six months after interferon therapy withdrawal, but can occur later, and even a few years after lamivudine withdrawal.…”

Section: Seroconversion Of Antigen E Of Hepatitis B Virus (Hbeag)mentioning

confidence: 99%

Response predictors to treatment with pegylated interferon in chronic hepatitis B

Ferreira

Tenore

2010

Braz J Infect Dis

View full text Add to dashboard Cite

The clinical and epidemiological importance of chronic B hepatitis is currently unquestionable as a cause of end-stage liver disease and hepatocellular carcinoma. Recently, predictors of treatment response of this disease have been studied, both before and during the course of medication. Therapy stopping rules have been proposed, which may be useful in patients presenting poor treatment tolerance. This review discusses the treatment response predictors usefulness, with emphasis on ALT, quantitative HBsAg and HBeAg, quantitative HBV-DNA and HBV genotyp

show abstract

“…IFN-α-induced HBeAg clearance has been reported to be durable in 80% to 90% of patients after long-term follow-up of 4 to 8 years. [10][11][12][13][14][15][16][17] However, HBV DNA remains detectable in serum in most of the patients. Studies comparing the outcome of responders versus non-responders found that patient who cleared HBeAg had better overall survival and survival free of hepatic de-compensation.…”

Section: Efficacy Resultsmentioning

confidence: 99%

“…Studies comparing the outcome of responders versus non-responders found that patient who cleared HBeAg had better overall survival and survival free of hepatic de-compensation. [10,11,13,18] Serum HBV DNA was assessed at baseline and end of therapy (16 weeks). After therapy, only 6 (20.68%) patients had HBV DNA level >10 7 copies/ml as compared to 14 (37.83%) patients at baseline.…”

Section: Efficacy Resultsmentioning

confidence: 99%

Effect of indigenous interferon - alpha on Hepatitis B virus deoxyribonucleic acid level in hepatitis b e antigen-positive chronic Hepatitis B patients

Rathi

Jain

2017

Indian J Med Sci

View full text Add to dashboard Cite

Background and Objective: HBeAg-positive chronic hepatitis B patients have high serum HBV DNA level showing high viral replication. Goal of treatment of hepatitis B is to prevent cirrhosis, hepatic failure and hepatocellular carcinoma by serum alanine transaminase (ALT) normalization, decrease in serum hepatitis B virus (HBV) deoxyribonucleic acid (DNA) and loss in hepatitis B e antigen (HBeAg). Interferons (IFNs) have antiviral, anti-proliferative, and immunomodulatory effects. IFN-α is effective in suppressing HBV replication and in inducing remission of liver disease. Materials and Methods: In this prospective, single treatment arm study, HBeAg-positive chronic hepatitis patients without decompensated liver disease were enrolled to receive indigenous recombinant IFN-α 2b in the dose of 5 MU daily for 6 days a week subcutaneously for 16 weeks. Quantitative HBV-DNA, HBeAg, and hepatitis B surface antigen (HBsAg) were assessed at baseline and at the end of treatment. ALT level assessment was done at baseline and during therapy at week 1, week 2, week 8, week 12, and week 16. Results: Out of 37 patients enrolled in the study, 8 patients (21.62%) did not complete study due to lost to follow-up (3 patients), discontinuation due to adverse event (3 patients), and consent withdrawal (2 patients). Among 29 patients who completed the study, 10 patients (34.48%) had clearance of HBeAg and 1 patient (3.44%) had lost HBsAg after 16 weeks of therapy. Mean ALT level started decreasing after 4 weeks of therapy but did not come to normal range till 16 weeks of therapy. At least 2 log decreases in HBV DNA was observed in 9 (31.03%) patients and at least 1 log decrease in 18 (62.06%) patients. Overall decline in HBV DNA level was observed in 62% patients after 16 weeks of therapy. Conclusion: IFN-α treatment does result in HBeAg and HBsAg loss and decreases HBV-DNA levels in chronic hepatitis B patients. Most of adverse events were mild to moderate in intensity. So, interferon-α therapy was well tolerated, safe, and efficacious to treat HBeAg-positive chronic hepatitis B patients without decompensated liver disease.

show abstract

Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa

Cited by 301 publications

References 1 publication

Durability of Serologic Response After Lamivudine Treatment of Chronic Hepatitis B

Durability of Serologic Response After Lamivudine Treatment of Chronic Hepatitis B

Response predictors to treatment with pegylated interferon in chronic hepatitis B

Effect of indigenous interferon - alpha on Hepatitis B virus deoxyribonucleic acid level in hepatitis b e antigen-positive chronic Hepatitis B patients

Contact Info

Product

Resources

About